Skip to main content

Table 3 Incidence of primary endpoint and each component according to the median of GA

From: Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

  Total population (n = 2247) Lower GA (≤ 14.4%, n = 1133) Higher GA (> 14.4%, n = 1114) P value
MACCE, n (%) 547 (24.3) 205 (18.1) 342 (30.7) < 0.001
All-cause death, n (%) 36 (1.6) 10 (0.9) 26 (2.3) 0.006
Non-fatal MI, n (%) 112 (5.0) 40 (3.5) 72 (6.5) 0.001
Non-fatal ischemic stroke, n (%) 45 (2.0) 22 (1.9) 23 (2.1) 0.835
Ischemia-driven revascularization, n (%) 354 (15.8) 133 (11.7) 221 (19.8) < 0.001
  1. GA glycated albumin, MACCE major adverse cardio-cerebral events, MI myocardial infarction